PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.10
Negative P/E while AGEN shows 6.07. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
13.16
Positive equity while AGEN shows negative equity. John Neff would investigate balance sheet advantage.
-12.69
Negative FCF while AGEN shows P/FCF of 5.98. Joel Greenblatt would examine cash flow improvement potential.
-12.81
Negative operating cash flow while AGEN shows P/OCF of 5.86. Joel Greenblatt would examine operational improvement potential.
13.16
Positive fair value while AGEN shows negative value. John Neff would investigate valuation advantage.
-8.06%
Negative earnings while AGEN shows yield of 4.12%. Joel Greenblatt would examine path to profitability.
-7.88%
Negative FCF while AGEN shows yield of 16.72%. Joel Greenblatt would examine cash flow improvement potential.